송수영 휴온스글로벌 대표 “합병 시 LO 앞당긴다” [현장+]

Huons Group's merger faces shareholder backlash over whether Huons Lab's KRW 129 billion valuation fairly accounts for potential licensing deals currently in negotiation. The dispute reveals a critical governance gap: biotech valuations may not transparently reflect pending technology transfer opportunities, creating information asymmetry between majority and minority shareholders.